Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
175
resultados
Última actualización
12/11/2026 [06:55:00]
Resumen de: WO2025155789A1
The present invention relates to novel chemical compounds of indane-, indene-, azaindane-, and azaindene-amines that act as 5-HT2A receptor agonists. These compounds are designed to offer improved therapeutic profiles for the treatment of a variety of neuropsychiatric, neurological, and neurodegenerative disorders. Also disclosed are methods for the synthesis and pharmaceutical use of these compounds.
Resumen de: WO2025146476A1
The present invention relates to compounds of formula (I) useful for modulating Triggering Receptor Expressed on Myeloid Cells-2 ("TREM2"). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TREM2, such as e.g. neurodegenerative diseases, and to pharmaceutical compositions comprising the compounds.
Resumen de: AU2025206055A1
The present invention relates to compounds of formula (I) useful for modulating Triggering Receptor Expressed on Myeloid Cells-2 ("TREM2"). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TREM2, such as e.g. neurodegenerative diseases, and to pharmaceutical compositions comprising the compounds.
Resumen de: WO2025151884A1
The present invention is directed to methods and compositions for the administration of sodium pentosan polysulfate and related glycosaminoglycans, particularly by oral administration, particularly in combination with administration of an intestinal penetration agent. The methods and compositions are suitable for treatment of neurodegenerative diseases such as, but not limited to, Alzheimer's disease. Methods and compositions according to the present invention can be used together with other agents suitable for treatment of neurodegenerative diseases such as, but not limited to, Alzheimer's disease.
Resumen de: CA3330167A1
The present invention relates to a series of compounds with an indazole structural core, which are capable of inhibiting the SGK1 enzyme. Accordingly, the invention also relates to the use of these compounds to treat neurodegenerative and/or cardiovascular diseases involving this enzyme, such as Parkinson's disease, Alzheimer's disease, myocardial infarction or high blood pressure.
Resumen de: US20260347847A1
The invention relates to the field of human genetics, more specifically neurological disorders. The invention in particular relates to the use of the antisense oligonucleotide AON1 with improved characteristics enhancing clinical applicability for treating Huntington as further defined herein.
Resumen de: US20260347941A1
0000 Presented herein are methods, systems, and a model useful in identifying a subject who has, or is at risk of developing Alzheimer's Disease (AD) and/or Mild Cognitive Impairment (MCI), or identifying a subject who has or is at risk of progressing from MCI to AD, or increasing in the severity of AD symptoms that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from 151a-3p, 151a-5p, 146a-5p, 4454, 10b-5p, 199a-3p, 199a-5p, 29b-3p, 126-5p, 150-5p, 107, let-7g-5p, 1290, 95-3p, 375-3p, 99a-5p, 125b-5p, 642a-5p, 92a-1-5p, 362-5p, 342-3p, 196a-5p, 155-5p, 409-3p, 744-5p, 223-3p, 584-5p, 340-5p, 421, 486-5p, 126-3p, 320c, 320b, let-7d-3p, 27b-3p, 148b-3p, 143-3p, 326, 335-5p, 25-3p, 153-3p, 19b-3p, let-7c-5p, 652-3p, 376c-3p, 154-5p, 376a-3p, 30d-5p, and 381-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of AD and/or MCI.
Resumen de: WO2026231057A1
The present disclosure provides a method of generating midbrain organoid comprising at least one culturing step performed under an oxygen concentration of 1% to 10%. In one embodiment, the culturing steps comprising (a) culturing pluripotent stem cells in a first culture medium to obtain embryoid bodies, (b) culturing the embryoid bodies in a second culture medium comprising a TGF-0 inhibitor, a BMP signaling inhibitor, a hedgehog signaling activator, and a Wnt signaling activator to obtain midbrain floor plate progenitor cells, (c) culturing the midbrain floor plate progenitor cells in a third culture medium comprising a fibroblast growth factor, and (d) culturing the midbrain floor plate progenitor cells in a fourth culture medium to obtain the midbrain organoid. The present disclosure further provides an isolated midbrain organoid obtained from the method, and uses of the cells isolated from said midbrain organoid in treating neurodegenerative diseases including Parkinson's disease.
Resumen de: US20260347408A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the peptide. The peptide of the present invention can be used to prevent fibrosis and oligomerization of amyloid beta, and thus can be used for the treatment and prevention of amyloidogenic disease such as Alzheimer's disease. In addition, the peptide of the present invention can be used to detect amyloid beta, and thus can be used for the diagnosis of amyloidogenic diseases such as Alzheimer's disease.
Resumen de: US20260345717A1
0000 Alzheimer's disease is treated with a composition including grapevine stem extract or a compound isolated therefrom as an effective component. As the grapevine stem extract and vitisin A as an effective component exhibit an excellent effect of inhibiting infection with the herpes simplex virus and inhibiting Alzheimer-causing factors in the brain tissue of animal models infected with the herpes simplex virus, the composition can be advantageously used as an agent for treating Alzheimer's disease or a functional health food or an animal feed additive for preventing or ameliorating Alzheimer's disease.
Resumen de: US20260345565A1
The present disclosure provides methods, compositions and kits for prophylactic treating or preventing a degenerative disease related to amyloid. The compositions and kits comprise Sigma-1 receptor agonist, an allosteric sigma agonist, and/or a dual agonist of Sigma-1 and M1. The compositions and kits elicit effects of delaying the onset, deterring the progress, and/or diminish the likelihood of the degenerative disease, such as deterring the memory loss and/or cognition decline in Alzheimer's disease.
Resumen de: US20260347760A1
0000 Summary 0000 The present invention relates to a new B. subtilis strain with positive influence on Alzheimer's disease.
Resumen de: WO2026227150A1
The present document describes compounds of formula (I) or a pharmaceutically acceptable salt thereof, or stereoisomers thereof, pharmaceutical compositions comprising a therapeutically effective amount of the compounds, and method, and/or use of the compounds for the treatment or prevention of neurodegenerative diseases including Alzheimer's disease, myastenic disease, mild dementia, or early dementia.
Resumen de: US20260347407A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's disease, comprising the peptide. When peptide SMA_04088-2 of the present invention is used, the fibrilization and oligomerization of amyloid beta can be prevented, and thus, the peptide SMA_04088-2 can be used in the treatment and prevention of amyloid diseases such as Alzheimer's disease. In addition, the peptide SMA_04088-2 can be used to detect amyloid beta, and thus can be used in the diagnosis of amyloid diseases such as Alzheimer's disease.
Resumen de: WO2026230982A1
Disclosed is a pharmaceutical composition for preventing or treating degenerative brain diseases, the pharmaceutical composition comprising lipid nanoparticles (LNPs) encapsulating mRNA expressing a chimeric antigen receptor (CAR) that specifically binds to amyloid-beta (Aβ), and mRNA expressing anti-inflammatory cytokine interleukin-10 (IL-10). The lipid nanoparticles are absorbed by peripheral monocytes or macrophages after intravenous administration in vivo, pass through the blood-brain barrier (BBB), move to brain tissue, and express Aβ-CAR and IL-10 in immune cells. Accordingly, an anti-inflammatory environment is induced at the same time as the selective removal of Aβ plaques, thereby inhibiting the pathological activation of microglia and promoting conversion to a homeostasis state. The present invention provides an in vivo gene therapy platform based on bifunctional immune cells, which simultaneously achieves Aβ removal and neuroinflammation inhibition, and is useful for the fundamental treatment of degenerative brain diseases including Alzheimer's disease.
Resumen de: WO2026231767A1
The present disclosure relates to compositions and methods for treating neurodegenerative diseases and disorders, e.g., Alzheimer's disease. The compositions of the present disclosure may comprise live bacterial cultures and/or prebiotic carbohydrates.
Resumen de: US20260345495A1
The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Resumen de: US20260348984A1
0000 Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's-negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: US20260345504A1
0000 The present invention relates to a composition and a method for treating Alzheimer's disease in a patient in need thereof. The method comprises administration to the patient of the composition comprising a therapeutically effective amount of extracellular vesicles, wherein the extracellular vesicles are isolated from culture medium of cells. In some embodiments, the extracellular vesicles comprise one or more of following miRNAs: let-7, miR-9, miR-21, miR-34a, and miR-10b.
Resumen de: US20260345527A1
0000 The present disclosure relates to a therapeutic composition for treating, preventing, inhibiting, improving, or slowing down a neurodegenerative disease, in particular a disease related to aggregate formation of TAR DNA-binding protein 43(TDP-43) such as amyotrophic lateral sclerosis, or the onset or development of such condition, by using a combination agent containing colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as active ingredients. The inventors of the present disclosure have confirmed that neurodegenerative diseases as described above may be treated or prevented by using a combination agent in which colchicine and metformin, which are drugs not used in the related art, are mixed as a therapeutic agent for conditions as described above.
Resumen de: US20260345604A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: GB2645437A
The present invention recognizes that there is an unmet need for the treatment of mild cognitive impairment. A first aspect of the present invention generally relates to a method of treating, relieving, or alleviating mild cognitive impairment in a subject. A second aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease in a subject. A third aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease Psychosis in a subject. A fourth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease behaviors, aggression, agitation, anger, apathy, or a combination thereof, in a subject. A fifth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Early Onset Alzheimer's Disease in a subject.
Resumen de: WO2026155973A1
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
Resumen de: WO2025140533A1
Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.
Nº publicación: EP4834343A1 04/11/2026
Solicitante:
KISSEI PHARMACEUTICAL [JP]
Kissei Pharmaceutical Co., Ltd.
Resumen de: EP4834343A1
0001 An object of the present invention is to provide a medicine that is a non-ergot DA, reduces a risk of somnolence as a side effect, and exhibits an excellent therapeutic effect against neurodegenerative diseases such as PD. 0002 The present invention relates to a pharmaceutical composition for treating a neurodegenerative disease such as Parkinson's disease including: 1-{(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno3,2-gquinoline-6-ylcarbonyl}-3-2-(dimethylamino)ethyl-1-propylurea or a pharmacologically acceptable salt thereof, wherein the compound is orally administered in an amount of 0.25 mg to 2 mg in terms of a free form equivalent value as a daily dose.
BOPI
Sede Electrónica
